References
- Cowen D, Richaud P, Mornex F, Bachelot T, Jung GM, Mirabel X, et al. Thymoma: results of a multicentric retrospective series of 149 non-metastatic irradiated patients and review of the literature. FNCLCC trialists. Federation Nationale des Centres de Lutte Contre le Cancer. Radiother Oncol 1995; 34: 9-16. doi: 10.1016/0167-8140(94)01493-m
- Levine GD, Rosai J. Thymic hyperplasia and neoplasia: a review of current concepts. Human Pathology 1978; 9: 495-515. doi: 10.1016/s0046-8177(78)80131-2
- Falkson CB, Bezjak A, Darling G, Gregg R, Malthaner R, Maziak DE, et al. The management of thymoma: a systematic review and practice guideline. J Thorac Oncol 2009; 4: 911-9. doi: 10.1097/jto.0b013e3181a4b8e0
- Okumura M, Ohta M, Tateyama H, Nakagawa K, Matsumura A, Maeda H, et al. The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer 2002; 94: 624-32. doi: 10.1002/cncr.10226
- Engels EA, Pfeiffer RM. Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer 2003; 105: 546-51. doi: 10.1002/ijc.11099
- Tomaszek S, Wigle DA, Keshavjee S, Fischer S. Thymomas: review of current clinical practice. Ann Thorac Surg 2009; 87: 1973-80. doi: 10.1016/j. athoracsur.2008.12.095
- Chau NG, Kim ES, Wistuba I. The multidisciplinary approach to thymoma: combining molecular and clinical approaches. J Thorac Oncol 2010; 5: S313-7. doi: 10.1097/JTO.0b013e3181f20d9a
- Miyamoto K, Acoba JD. Thymomas and thymic carcinomas: a review on pathology, presentation, staging, treatment, and novel systemic therapies. EMJ Respir 2017; 5: 100-7. doi: 10.33590/emjrespir/10310358
- Peric J, Samaradzic N, Skodric Trifunovic V, Tosic N, Stojsic J, Pavlovic S, et al. Genomic profiling of thymoma using a targeted high-throughput approach. Arch Med Sci 2020. doi: 10.5114/aoms.2020.96537
- Slatko BE, Gardner AF, Ausubel FM. Overview of next-generation sequencing technologies. Curr Protoc Mol Biol 2018; 122: e59. doi: 10.1002/cpmb.59
- Duncavage EJ, Abel HJ, Szankasi P, Kelley TW, Pfeifer JD. Targeted next generation sequencing of clinically significant gene mutations and translocations in leukemia. Mod Pathol 2012; 25: 795-804. doi: 10.1038/modpathol.2012.29
- Xu H, DiCarlo J, Satya RV, Peng Q, Wang Y. Comparison of somatic mutation calling methods in amplicon and whole exome sequence data. BMC Genomics 2014; 15: 244. doi: 10.1186/1471-2164-15-244
- Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, et al. OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol 2017; 2017: PO.17.00011. doi: 10.1200/PO.17.00011
- Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidem 2009; 62: e1-34. doi: 10.1016/j.jclinepi.2009.06.006
- Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page M J, et al. A Cochrane handbook for systematic reviews of interventions. Cochrane handbook for systematic reviews of interventions. 2019. (cited 2022 Dec 19). Available at:
https://training.cochrane.org/handbook - Cohrain Training. RevMan 5. (accessed 2021 Aug 3). Available at:
https://training.cochrane.org/online-learning/core-software-cochrane-reviews/revman/revman-5-download - Girard N, Basse C, Schrock A, Ramkissoon S, Killian K, Ross JS. Comprehensive genomic profiling of 274 thymic epithelial tumors unveils oncogenic pathways and predictive biomarkers. Oncologist 2022; 27: 919-29. doi: 10.1093/oncolo/oyac115
- Szpechcinski A, Szolkowska M, Winiarski S, Lechowicz U, Wisniewski P, Knetki-Wroblewska M. Targeted next-generation sequencing of thymic epithelial tumours revealed pathogenic variants in KIT, ERBB2, KRAS, and TP53 in 30% of thymic carcinomas. Cancers 2022; 14: 3388. doi: 10.3390/cancers14143388
- GeneCards® The Human Gene Database. (Updated: 2023 Jan 10). Available at:
https://www.genecards.org/ - Müllauer L. GTF2I gene mutation – a driver of thymoma pathogenesis. Mediastinum 2017; 1: 11. doi: 10.21037/med.2017.11.03
- Feng Y, Lei Y, Wu X, Huang Y, Rao H, Zhang Y, et al. GTF2I mutation frequently occurs in more indolent thymic epithelial tumors and predicts better prognosis. Lung Cancer 2017; 110: 48-52. doi: 10.1016/j.lungcan.2017.05.02022
- Radovich M, Pickering CR, Felau I, Ha G, Zhang H, Jo H, et al. The integrated genomic landscape of thymic epithelial tumors. Cancer Cell 2018; 33: 244-58.e10. doi: 10.1016/j.ccell.2018.01.003
- Liu D, Zhang P, Zhao J, Yang L, Wang W. Identification of molecular characteristics and new prognostic targets for thymoma by multiomics analysis. BioMed Res Int 2021; 2021: Article ID 5587441, 1-15. doi: 10.1155/2021/5587441
- TCGA’s Study of Thymoma. (cited 2022 Dec 5). Available at:
https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga/studied-cancers/thymoma - Venuta F, Rendina EA, Anile M, de Giacomo T, Vitolo D, Coloni GF. Thymoma and thymic carcinoma. Gen Thorac Cardiovasc Surg 2012; 60: 1-12. doi: 10.1007/s11748-011-0814-0
- Petrini I, Meltzer PS, Kim IK, Lucchi M, Park KS, Fontanini G, et al. A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. Nature Genetics 2014; 46: 844-9. doi: 10.1038/ng.3016
- Higuchi R, Goto T, Hirotsu Y, Yokoyama Y, Nakagomi T, Otake S, et al. Primary driver mutations in GTF2I specific to the development of thymomas. Cancers 2020; 12: 1-12. doi: 10.3390/cancers12082032
- Liang NX, Liu L, Huang C, Liu HS, Guo C, Li J, et al. Transcriptomic and mutational analysis discovering distinct molecular characteristics among chinese thymic epithelial tumor patients. Front Oncol 2021; 11: 647512. doi: 10.3389/fonc.2021.647512
- Hafner A, Bulyk ML, Jambhekar A, Lahav G. The multiple mechanisms that regulate p53 activity and cell fate. Nat Rev Mol Cell Biol 2019; 20: 199-210. doi: 10.1038/s41580-019-0110-x
- Marx A, Belharazem D, Lee DH, Popovic ZV, Reissfelder C, Schalke B, et al. Molecular pathology of thymomas: implications for diagnosis and therapy. Virchows Arch 2021; 478: 101-10. doi: 10.1007/s00428-021-03068-8
- Chen K, Che JM, Zhang XF, Jin RS, Xiang J, Han DP, et al. Next-generation sequencing in thymic epithelial tumors uncovered novel genomic aberration sites and strong correlation between TMB and MSH6 single nucleotide variations. Cancer Letters 2020; 476: 75-86. doi: 10.1016/j.canlet.2020.02.001
- Xu S, Li XF, Zhang HY, Zu LL, Yang LQ, Shi T, et al. Frequent genetic alterations and their clinical significance in patients with thymic epithelial tumors. Front Oncol 2021; 11: 667148. doi: 10.3389/fonc.2021.667148
- Jovanovic D, Markovic J, Ceriman V, Peric J, Pavlovic S, Soldatovic I. Correlation of genomic alterations and PD-L1 expression in thymoma. J Thorac Dis 2020; 12: 7561-70. doi: 10.21037/jtd-2019-thym-13
- Enkner F, Pichlhöfer B, Zaharie AT, Krunic M, Holper TM, Janik S, et al. Molecular profiling of thymoma and thymic carcinoma: genetic differences and potential novel therapeutic targets. Pathol Oncol Res 2017; 23: 551-64. doi: 10.1007/s12253-016-0144-8
- Rajan A, Girard N, Marx A. State of the art of genetic alterations in thymic epithelial tumors. J Thorac Oncol 2014; 9: S131-S6. doi: 10.1097/JTO.0000000000000298
- Sakane T, Murase T, Okuda K, Saida K, Masaki A, Yamada T, et al. A mutation analysis of the EGFR pathway genes, RAS, EGFR, PIK3CA, AKT1 and BRAF, and TP53 gene in thymic carcinoma and thymoma type A/B3. Histopathology 2019; 75: 755-66. doi: 10.1111/his.13936